High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial | NeoGenomics Laboratories

Publication date

Thu, 02/02/2023 - 12:00

Year

Subtitle

Nature

External link

https://www.nature.com/articles/s41591-022-02199-y

Division